Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma

Please always quote using this URN: urn:nbn:de:bvb:20-opus-265635
  • Background Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are limited to the PD-L1 inhibitor avelumab. For avelumab-refractory patients, efficient and safe treatment options are lacking. Methods At three different sites in Germany, clinical and molecular data of patients with metastatic MCC being refractory to the PD-L1 inhibitor avelumab and who were later on treated with combined IPI/NIVO were retrospectively collected andBackground Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis. In Europe, approved systemic therapies are limited to the PD-L1 inhibitor avelumab. For avelumab-refractory patients, efficient and safe treatment options are lacking. Methods At three different sites in Germany, clinical and molecular data of patients with metastatic MCC being refractory to the PD-L1 inhibitor avelumab and who were later on treated with combined IPI/NIVO were retrospectively collected and evaluated. Results Five patients treated at three different academic sites in Germany were enrolled. Three out of five patients investigated for this report responded to combined IPI/NIVO according to RECIST 1.1. Combined immunotherapy was well tolerated without any grade II or III immune-related adverse events. Two out of three responders to IPI/NIVO received platinum-based chemotherapy in between avelumab and combined immunotherapy. Conclusion In this small retrospective study, we observed a high response rate and durable responses to subsequent combined immunotherapy with IPI/NIVO in avelumab-refractory metastatic MCC patients. In conclusion, our data suggest a promising activity of second- or third-line PD-1- plus CTLA-4-blockade in patients with anti-PD-L1-refractory MCC.show moreshow less

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Metadaten
Author: Valerie Glutsch, Hermann Kneitz, Anja Gesierich, Matthias Goebeler, Sebastian Haferkamp, Jürgen C. Becker, Selma Ugurel, Bastian Schilling
URN:urn:nbn:de:bvb:20-opus-265635
Document Type:Journal article
Faculties:Medizinische Fakultät / Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
Language:English
Parent Title (English):Cancer Immunology, Immunotherapy
ISSN:14320851
Year of Completion:2021
Volume:70
Issue:7
Pagenumber:2087-2093
Source:Cancer Immunology, Immunotherapy 2021, 70(7):2087-2093. DOI: 10.1007/s00262-020-02832-0
DOI:https://doi.org/10.1007/s00262-020-02832-0
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/33439294
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Tag:Merkel cell carcinoma; avelumab; ipilimumab; nivolumab; resistance
Release Date:2022/07/26
Licence (German):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International